knowledge -WSS

knowledge

author：leisure time 2025-09-29 06:52:38 - browse：36632

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Will biotech layoffs continue through 2023?

WSS

Gilead might be held responsible for not developing a drug

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Medicare Advantage proposed rates disappoint insurers

Biogen Alzheimer’s drug launch off to slow start

Key House Republican on health care plans exit from Congress

Trump allegedly attempted to have surveillance video deleted: Special Counsel

focus

knowledge

explore

As demand for Covid shots wanes, Moderna seeks its next success

Robert F. Kennedy is pitching centrism on health, even on abortion

Novavax promises a turnaround & Lilly roils the obesity market

Behind warning on Apellis’s eye drug lies a conflict of interest

Heart attack and stroke risk calculators need revising

Biogen Alzheimer’s drug launch off to slow start

Cancer drug shortages should be causing more outrage

KalVista pill reduced swelling 'attacks' caused by genetic disease

Psychedelics group wrestles with new pharma identity

Biden report: The neurospychology of memory and aging

explore

Industry veterans launch new biotech VC with $310M

Ending health disparities requires full federal government, panel says

KalVista pill reduced swelling 'attacks' caused by genetic disease

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Timeline: Special counsel's probe into Trump's handling of classified documents

What we’ve learned from the Aduhelm mess

knowledge

hotspot

hotspot

hotspot